- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06359847
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
April 6, 2024 updated by: Beijing Scitech-Mq Pharmaceuticals Limited
A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy
ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc.
The primary purpose of this study is to evaluate the efficacy of ST-1898 tablets in patients with locally advanced or metastatic RAIR-DTC after failure of at least first-line TKI systemic therapy.
All subjects will receive ST-1898 180 mg orally once daily until disease progression or intolerable toxicity.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yansong Lin, MD
- Phone Number: 0086-10-69151188
- Email: linyansong1968@163.com
Study Contact Backup
- Name: Xin Zhang, MD
- Phone Number: 0086-10-69151188
- Email: zhangxin37@pumch.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Xin Zhang, MD
-
Contact:
- Yansong Lin, MD
-
Principal Investigator:
- Yansong Lin, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age >= 18 years
- Life expectancy of twelve weeks or more
- Histologically or cytologically confirmed locally advanced or metastatic DTC that cannot be removed by surgery or radiotherapy, including papillary thyroid cancer, follicular thyroid cancer, hurthle cell thyroid cancer or poorly differentiated thyroid cancer.
- At least one measurable lesion according to RECIST 1.1
Participants must be radioiodine (131I)- refractory / resistant as defined by at least one of the following criteria:
- One or more measurable lesions that do not demonstrate iodine uptake on any radioiodine scan.
- One or more measurable lesions that has progressed as per RECIST 1.1 within 14 months of 131I therapy(3.7~7.4 GBq or100~200 mCi),despite demonstration of radioiodine avidity at the time of that treatment by pre- or post-treatment scanning.
- Cumulative activity of 131I of > 22 GBq or 600 mCi, with the last dose administered at least 6 months prior to study entry
- Patients with DTC must have "progressed on" after at least first-line TKI systemic therapy.
- Tumor tissue sections available (Formalin fixed and paraffin-embedded wax chunks of tumor tissue or unstained specimen).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- TSH-suppression therapy is well tolerated with thyroid stimulating hormone (TSH) < 0.5 mU/L;
The patient has adequate organ and bone marrow function as follows:
- Adequate bone marrow function (without transfusion or growth factor support within 2 weeks): hemoglobin ≥ 90 g/L, absolute neutrophil count (ANC) ≥ 1.5 ×109/L and platelets ≥ 90 × 109/L;
- Adequate liver function: Bilirubin ≤ 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if participant has liver metastases);
- Adequate renal function: Serum creatinine ≤1.5 ×ULN or creatinine clearance≥50 mL/min per the Cockcroft-Gault formula;
- Adequate blood coagulation function: International Normalized Ratio (INR) ≤ 1.5 and Activated partial thromboplastin time (APTT) ≤1.5 ULN(except for the prophylactic use of anticoagulants)
- Adequate cardiac function: Left ventricular ejection fraction (LVEF) ≥50%;
- Participants having≤ 1 + proteinuria or ≥2+ proteinuria with urine protein < 1 g/24 hour (h).
- Ability to understand and the willingness to sign a written informed consent document. The results of routine examination during the corresponding window period before screening are acceptable.
- Women with child-bearing potential and men must agree to use adequate contraception (e.g., hormonal contraceptives, male or female condom, or abstinence) during the course of the study and for at least 3 months following the last dose of study drug. Women with childbearing potential must have a negative serum pregnancy test within 7 days before first study treatment.
Exclusion Criteria:
- Other histological subtypes of thyroid cancer (such as Anaplastic or medullary carcinoma of the thyroid).
- Known hypersensitivity to any component of ST-1898 tablets.
- Participants who have received any antitumor treatment within 4 weeks or 5 half-lives of the agent (contingent on the shorter time) prior to the first dose of study drug.
- Patients who underwent major surgery, open biopsy or significant traumatic injury within 4 weeks prior to the first dose of study drug.
- Serious non-healing wound/ulcer/bone fracture.
- ≥ grade 3 bleeding episodes within 6 months prior to first dose of study treatment, or currently ≥ grade 2 hemorrhage, with high bleeding risks (such as coagulation disorders, tracheobronchial infiltration with significant bleeding, active gastritis/duodenal ulcer and esophageal varices)
- Active hemoptysis or more than 0.5 teaspoon (2.5 mL) of hemoptysis per day within 2 months before first dose of study treatment
- Subjects with antiplatelet agents treatment (low-dose aspirin ≤100 mg/day is permitted).
- Current or previous severe retinopathy who, in the judgment of the Investigator or specialist, are not suitable for enrollment
Significant cardiovascular impairment, including but not limited to:
- Serious arrhythmia or cardiac conduct abnormality, such as degree II-III atrioventricular block or ventricular arrhythmia needs to be treated.
- QTcF interval extension (by the Fridericia formula): male >450 ms, female >480 ms
- Acute coronary syndrome, stroke, deep vein thrombosis, pulmonary- thromboembolism, arterial thrombosis, congestive heart failure, aortic dissection etc.
- New York Heart Association Class ≥ II
- Uncontrolled hypertension, as defined by a sustained blood pressure (BP) > 140/90 mHg with two or more antihypertensive treatment.
- Known brain metastasis or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and with a stable dose of corticosteroid treatment before first dose of study treatment.
- Interstitial lung disease or radiation pneumonia in need of glucocorticoids intervention
- Previous or currently malignant tumors (not including non-melanoma skin cancer, breast cancer or cervical cancer in situ, and superficial bladder transient cell carcinoma under control in the last 5 years)
- Receiving chronic concomitant treatment of strong CYP3A4 inducers, CYP3A4 inhibitors or CYP3A4 substrate with a narrow therapeutic window within 2 weeks prior to study drug administration,
- Prior treatment of cabozantinib or BRAF inhibitors.
- Has not recovered from toxicities caused by prior therapy to CTCAE ≤Grade 1 (except for ≤Grade 2 peripheral neuropathy, alopecia, and other events judged tolerable by the Investigator and without safety risks).
- Active hepatitis B (asymptomatic hepatitis B carriers with HBV DNA< the lower limit of the reference range), hepatitis C virus (HCV) antibody-positive and HCV-RNA- positive, or other active hepatitis, clinically significant moderate-to-severe cirrhosis. Prophylactic antiviral therapy other than interferon are allowed.
- Acute bacterial, viral or fungal infections (any infection requiring systemic treatment)
- Females who are pregnant or breastfeeding.
- Drug or alcohol dependents.
- Significant disorder of neurology or mental disease or poorly compliance.
- Subjects with oral administration impossible, or in the conditions of malabsorption as determined by the investigator, such as dysphagia and intestinal obstruction, etc..
- Uncontrolled pleural effusion, pericardial effusion, abdominal effusion requiring frequent drainage or medical intervention (clinically significant recurrence requiring additional intervention within 2 weeks after intervention, excluding exudate cytology) before first dose of study treatment.
- Any history of other serious systemic diseases, or any other reason that might interfere with participation in trial or interfere with interpretation of trial results, in the judgement of the Investigator, that are not qualified to participate in this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ST-1898
All participants will be administered with ST-1898 orally at 180mg once daily during the study, until disease progression or intolerable toxicity.
|
Tablets: 5 mg and 40 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to 24 months
|
ORR is defined as the proportion of patients who have had a PR or CR as assessed by the RECIST 1.1.
(CR: Complete Response, Disappearance of all target lesions, PR: Partial Response, >=30% decrease in the sum of the longest diameters of target lesions).
Overall Response (OR) = CR + PR
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number and frequency of treatment-related adverse events (AEs) and treatment related serious adverse events (SAEs)
Time Frame: Up to 24 months
|
AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.
|
Up to 24 months
|
PFS
Time Frame: Up to 24 months
|
Progression-Free Survival (PFS) per RECIST 1.1
|
Up to 24 months
|
PFS6m
Time Frame: up to 24 months
|
PFS6m per RECIST 1.1
|
up to 24 months
|
DCR
Time Frame: up to 24 months
|
Disease Control Rate (DCR) per RECIST 1.1
|
up to 24 months
|
DOR
Time Frame: up to 24 months
|
Duration of Response (DOR) per RECIST 1.1
|
up to 24 months
|
OS
Time Frame: up to 24 months
|
Overall Survival (OS) per RECIST 1.1
|
up to 24 months
|
Thyroglobulin (Tg)
Time Frame: Up to 24 months
|
Correlation analysis between Tg and efficacy of ST-1898
|
Up to 24 months
|
Thyroglobulin Antibody (TgAb)
Time Frame: Up to 24 months
|
Correlation analysis between TgAb and efficacy of ST-1898
|
Up to 24 months
|
Pharmacokinetic (PK) Parameter: Tmax
Time Frame: On Day 1 from Cycle 1 to Cycle 4 (21 days per cycle), up to 12 weeks
|
Time to Peak Plasma Concentration.
|
On Day 1 from Cycle 1 to Cycle 4 (21 days per cycle), up to 12 weeks
|
Pharmacokinetic (PK) Parameter: T1/2
Time Frame: On Day 1 from Cycle 1 to Cycle 4 (21 days per cycle), up to 12 weeks
|
Terminal Elimination Half-life.
|
On Day 1 from Cycle 1 to Cycle 4 (21 days per cycle), up to 12 weeks
|
Pharmacokinetic (PK) Parameter: Cmax
Time Frame: On Day 1 from Cycle 1 to Cycle 4 (21 days per cycle), up to 12 weeks
|
Maximum Plasma Concentration.
|
On Day 1 from Cycle 1 to Cycle 4 (21 days per cycle), up to 12 weeks
|
Pharmacokinetic (PK) Parameter: AUC
Time Frame: On Day 1 from Cycle 1 to Cycle 4 (21 days per cycle), up to 12 weeks
|
Area Under the Curve of ST-1898 plasma concentration-time curve.
|
On Day 1 from Cycle 1 to Cycle 4 (21 days per cycle), up to 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yansong Lin, Ph D, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2023
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
January 3, 2024
First Submitted That Met QC Criteria
April 6, 2024
First Posted (Actual)
April 11, 2024
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 6, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ST-1898-202
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Differentiated Thyroid Carcinoma
-
Providence Health & ServicesRecruitingBRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedPoorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingPoorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditionsUnited States, Taiwan, Australia, Singapore, China
-
National Cancer Institute (NCI)TerminatedThyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid CancerUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
University of WuerzburgDeutsche Krebshilfe e.V., Bonn (Germany)RecruitingDifferentiated Thyroid CarcinomaGermany
-
Peking University Cancer Hospital & InstituteCompletedDifferentiated Thyroid Carcinoma (DTC)
-
Peking Union Medical College HospitalNot yet recruitingLocally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid CarcinomaChina
Clinical Trials on ST-1898 tablets
-
Beijing Scitech-Mq Pharmaceuticals LimitedRecruitingUnresectable or Metastatic MelanomaChina
-
Nanyang Technological UniversityActive, not recruitingPhysiological Outcomes of High-intensity Interval Training With Post-exercise Blood Flow RestrictionExercise PerformanceSingapore
-
Abbott Medical DevicesTerminatedCoronary Artery DiseaseUnited States
-
St Stephens Aids TrustUniversity of Turin, Italy; University of LiverpoolCompleted
-
Istituto Superiore di Osteopatia di MilanoCompletedHealthy | Osteopathic ManipulationItaly
-
Max Zeller Soehne AGCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingPeripheral NeuropathyUnited States
-
University Hospitals Coventry and Warwickshire...RecruitingNervous System Diseases | Neuromuscular Diseases | Respiratory Failure | Respiratory Insufficiency | Amyotrophic Lateral Sclerosis | Sleep-Disordered Breathing | Neuro-Degenerative Disease | Neuron Disease, MotorUnited Kingdom
-
University of ThessalyRecruiting
-
SIGA TechnologiesNational Institute of Allergy and Infectious Diseases (NIAID)Completed